| 0.415 -0.015 (-3.49%) | 12-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.62 |
1-year : | 0.72 |
| Resists | First : | 0.53 |
Second : | 0.62 |
| Pivot price | 0.45 |
|||
| Supports | First : | 0.39 | Second : | 0.33 |
| MAs | MA(5) : | 0.43 |
MA(20) : | 0.45 |
| MA(100) : | 0.44 |
MA(250) : | 0.39  |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 11.9 |
D(3) : | 16.5 |
| RSI | RSI(14): 36.8 |
|||
| 52-week | High : | 0.73 | Low : | 0.2 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CYBN ] has closed below the lower bollinger band by 2.9%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 45.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.43 - 0.43 | 0.43 - 0.44 |
| Low: | 0.4 - 0.41 | 0.41 - 0.41 |
| Close: | 0.42 - 0.43 | 0.43 - 0.44 |
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
Wed, 06 Dec 2023
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Program - Business Wire
Tue, 05 Dec 2023
Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual ... - Business Wire
Thu, 30 Nov 2023
Cybin reports positive Phase 2 data for depression drug, files SEC Form D - Seeking Alpha
Thu, 30 Nov 2023
Cybin Inc (CYBN) Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder - StreetInsider.com
Wed, 29 Nov 2023
Should Biotechnology Stock Cybin Inc (CYBN) Be in Your Portfolio Wednesday? - InvestorsObserver
Wed, 15 Nov 2023
Cybin Expects Phase 3 Data on CYB003 in 2024 - Green Market Report
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|